- Home
- AIRS vs SLS Comparison
AIRS vs SLS Comparison
Compare AIRS & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- SLS
- Stock Information
- Founded
- AIRS 2012
- SLS 2012
- Country
- AIRS United States
- SLS United States
- Employees
- AIRS N/A
- SLS N/A
- Industry
- AIRS Medical/Nursing Services
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- SLS Health Care
- Exchange
- AIRS Nasdaq
- SLS Nasdaq
- Market Cap
- AIRS 166.3M
- SLS 169.6M
- IPO Year
- AIRS 2021
- SLS N/A
- Fundamental
- Price
- AIRS $4.63
- SLS $1.64
- Analyst Decision
- AIRS Hold
- SLS
- Analyst Count
- AIRS 3
- SLS 0
- Target Price
- AIRS $3.75
- SLS N/A
- AVG Volume (30 Days)
- AIRS 558.2K
- SLS 2.9M
- Earning Date
- AIRS 05-02-2025
- SLS 05-13-2025
- Dividend Yield
- AIRS N/A
- SLS N/A
- EPS Growth
- AIRS N/A
- SLS N/A
- EPS
- AIRS N/A
- SLS N/A
- Revenue
- AIRS $172,101,000.00
- SLS N/A
- Revenue This Year
- AIRS N/A
- SLS N/A
- Revenue Next Year
- AIRS $5.46
- SLS N/A
- P/E Ratio
- AIRS N/A
- SLS N/A
- Revenue Growth
- AIRS N/A
- SLS N/A
- 52 Week Low
- AIRS $1.53
- SLS $0.77
- 52 Week High
- AIRS $9.20
- SLS $2.12
- Technical
- Relative Strength Index (RSI)
- AIRS 77.74
- SLS 50.83
- Support Level
- AIRS $4.16
- SLS $1.36
- Resistance Level
- AIRS $4.57
- SLS $1.83
- Average True Range (ATR)
- AIRS 0.39
- SLS 0.18
- MACD
- AIRS 0.06
- SLS -0.03
- Stochastic Oscillator
- AIRS 88.34
- SLS 28.36
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.